Targeting c-Met in melanoma: Mechanism of resistance and efficacy of novel combinatorial inhibitor therapy

Cancer Biology and Therapy

Volumn 15, Issue 9, 2014, Pages 1129-1141

  Etnyre, Deven ^a   Stone, Amanda L ^a   Fong, Jason T ^a   Jacobs, Ryan J ^a   Uppada, Srijayaprakash B ^a   Botting, Gregory M ^a   Rajanna, Supriya ^a   Moravec, David N ^a   Shambannagari, Manohar R ^a   Crees, Zachary ^a   Girard, Jennifer ^a   Bertram, Ceyda ^a   Puri, Neelu ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

BRAF; c Met; Melanoma; mTOR; Resistance; SU11274; Wnt

Indexed keywords

((3Z)-N-(3-CHLOROPHENYL)-3-((3,5-DIMETHYL-4-((4-METHYLPIPERAZIN-1-YL)CARBONYL)-1H-PYRROL-2-YL)METHYLENE)-N-METHYL-2-OXO-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE); 7,8 DIHYDRO 2 [4 (TRIFLUOROMETHYL)PHENYL] 5H THIOPYRANO[4,3 D]PYRIMIDIN 4 OL; ANTINEOPLASTIC AGENT; EVEROLIMUS; FUSED HETEROCYCLIC RINGS; HUMAN GROWTH HORMONE; INDOLE DERIVATIVE; JNJ38877605; MTOR PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE; RAPAMYCIN; SCATTER FACTOR RECEPTOR; SULFONAMIDE; TARGET OF RAPAMYCIN KINASE; WNT PROTEIN; WNT7B PROTEIN, HUMAN;

ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; MALE; MELANOMA; METABOLISM; MUTATION; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HETEROCYCLIC COMPOUNDS, 3-RING; HETEROGRAFTS; HUMAN GROWTH HORMONE; HUMANS; INDOLES; MALE; MELANOMA; MICE, INBRED BALB C; MICE, NUDE; MUTATION; PHOSPHORYLATION; PIPERAZINES; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDAZINES; SIGNAL TRANSDUCTION; SIROLIMUS; SKIN NEOPLASMS; SULFONAMIDES; TOR SERINE-THREONINE KINASES; WNT PROTEINS;

EID: 84906854269     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.29451     Document Type: Article

References (89)

1. Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T, Jagadeeswaran R, Salgia R. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 2007; 13:2246-53; PMID:17404109; http://dx.doi.org/10.1158/1078-0432.CCR-06-0776
2. Lee YJ, Kim DH, Lee SH, Kim DW, Nam HS, Cho MK. Expression of the c-Met Proteins in Malignant Skin Cancers. Ann Dermatol 2011; 23:33-8; PMID:21738360; http://dx.doi.org/10.5021/ad.2011.23.1.33
3. Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, Schmidt L, Zbar B, Vande Woude GF. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000; 19:4947-53; PMID:11042681; http://dx.doi.org/10.1038/sj. onc.1203874
4. Nakamura T, Sakai K, Nakamura T, Matsumoto K. Hepatocyte growth factor twenty years on: Much more than a growth factor. J Gastroenterol Hepatol 2011; 26(Suppl 1):188-202; PMID:21199531; http://dx.doi.org/10.1111/j.1440-1746.2010. 06549.x
5. Vergani E, Vallacchi V, Frigerio S, Deho P, Mondellini P, Perego P, Cassinelli G, Lanzi C, Testi MA, Rivoltini L, et al. Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia 2011; 13:1132-42; PMID:22241959
6. Sharma A, Shah SR, Illum H, Dowell J. Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies. Drugs 2012; 72:2207-22; PMID:23116250; http://dx.doi.org/10.2165/ 11640870-000000000-00000
7. Dummer R, Flaherty KT. Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Curr Opin Oncol 2012; 24:150- 4; PMID:22316627; http://dx.doi.org/10.1097/CCO.0b013e32834fca92
8. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33:19-20; PMID:12447372; http://dx.doi.org/10.1038/ng1054
9. Kelleher FC, McArthur GA. Targeting NRAS in melanoma. Cancer J 2012; 18:132-6; PMID:22453013; http://dx.doi.org/10.1097/PPO.0b013e31824ba4df
10. Chattopadhyay C, Ellerhorst JA, Ekmekcioglu S, Greene VR, Davies MA, Grimm EA. Association of activated c-Met with NRAS-mutated human melanomas. Int J Cancer 2012; 131:E56-65; PMID:22020736; http://dx.doi.org/10.1002/ijc.26487
11. Sattler M, Salgia R. c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep 2007; 9:102-8; PMID:17288874; http://dx.doi.org/10.1007/s11912-007-0005-4
12. Kim ES, Salgia R. MET pathway as a therapeutic target. J Thorac Oncol 2009; 4:444-7; PMID:19333071; http://dx.doi.org/10.1097/JTO.0b013e31819d6f91
13. Otsuka T, Takayama H, Sharp R, Celli G, LaRochelle WJ, Bottaro DP, Ellmore N, Vieira W, Owens JW, Anver M, et al. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res 1998; 58:5157-67; PMID:9823327
14. Cruz J, Reis-Filho JS, Silva P, Lopes JM. Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas. Oncology 2003; 65:72-82; PMID:12837985; http://dx.doi.org/10.1159/000071207
15. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang C, Podar K, Christensen JG, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 2003; 63:5462-9; PMID:14500382
16. Cepero V, Sierra JR, Corso S, Ghiso E, Casorzo L, Perera T, Comoglio PM, Giordano S. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res 2010; 70:7580-90; PMID:20841479; http://dx.doi.org/10.1158/0008-5472.CAN-10-0436
17. King P, Jansens B, Verhulst T, Argent R, Kumari R, Watson S, Andries L, Mevellec L, Page M, Perera T. JNJ-38877605: A selective oral Met inhibitor for the treatment of cancer. Cancer Res [Internet] 2010; 70(8 Suppl):Abstract 3628. Available from: http://cancerres.aacrjournals.org/cgi/content/meeting-abstract/ 70/8-MeetingAbstracts/3628
18. Perera T, Lavrijssen T, Janssens B, Geerts T, King P, Mevellec L, Cummings M, Lu T, Johnson D, Page M. JNJ-38877605: a selective Met kinase inhibitor inducing regression of Met-driven tumor models. Presented at the 99th AACR Annual Meeting; 2008 Apr 12-16; San Diego (CA): Abstract nr 4837.
19. Qi J, McTigue MA, Rogers A, Lifshits E, Christensen JG, Jänne PA, Engelman JA. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res 2011; 71:1081-91; PMID:21266357; http://dx.doi.org/10.1158/0008-5472.CAN-10-1623
20. Sierra JR, Cepero V, Giordano S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer 2010; 9:75; PMID:20385023; http://dx.doi.org/10.1186/1476-4598-9-75
21. Sierra JR, Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol 2011; 3(Suppl):S21-35; PMID:22128285; http://dx.doi.org/10.1177/1758834011422557
22. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011; 10:2298-308; PMID:21926191; http://dx.doi.org/10.1158/ 1535-7163.MCT-11-0264
23. Gordon SM, Kluger HM, Shapiro G, Kurzrock R, Edelman G, Samuel TA, Moussa AH, Ramies DA, Laird AD, Schimmoller F, et al. Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 2012; 30(suppl): abstr 8531. Available from: http://meetinglibrary.asco.org/content/94473-114
24. He X, Semenov M, Tamai K, Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development 2004; 131:1663-77; PMID:15084453; http://dx.doi.org/10.1242/dev.01117
25. Zeng X, Huang H, Tamai K, Zhang X, Harada Y, Yokota C, Almeida K, Wang J, Doble B, Woodgett J, et al. Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development 2008; 135:367-75; PMID:18077588; http://dx.doi.org/10. 1242/dev.013540
26. Lee E, Salic A, Krüger R, Heinrich R, Kirschner MW. The roles of APC and Axin derived from experimental and theoretical analysis of the Wnt pathway. PLoS Biol 2003; 1:E10; PMID:14551908; http://dx.doi.org/10.1371/journal.pbio. 0000010
27. Salic A, Lee E, Mayer L, Kirschner MW. Control of beta-catenin stability: reconstitution of the cytoplasmic steps of the wnt pathway in Xenopus egg extracts. Mol Cell 2000; 5:523-32; PMID:10882137; http://dx.doi.org/10.1016/ S1097-2765(00)80446-3
28. Kim MJ, Chia IV, Costantini F. SUMOylation target sites at the C terminus protect Axin from ubiquitination and confer protein stability. FASEB J 2008; 22:3785-94; PMID:18632848; http://dx.doi.org/10.1096/fj.08-113910
29. Adachi Y, Shibai Y, Mitsushita J, Shang WH, Hirose K, Kamata T. Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6. Oncogene 2008; 27:4921-32; PMID:18454176; http://dx.doi.org/10.1038/onc.2008.133
30. Bhattacharya S, Mathew G, Jayne DG, Pelengaris S, Khan M. 15-lipoxygenase-1 in colorectal cancer: a review. Tumour Biol 2009; 30:185-99; PMID:19752603; http://dx.doi.org/10.1159/000236864
31. Weidenfeld J, Shu W, Zhang L, Millar SE, Morrisey EE. The WNT7b promoter is regulated by TTF-1, GATA6, and Foxa2 in lung epithelium. J Biol Chem 2002; 277:21061-70; PMID:11914369; http://dx.doi.org/10.1074/jbc.M111702200
32. Zhong Y, Wang Z, Fu B, Pan F, Yachida S, Dhara M, Albesiano E, Li L, Naito Y, Vilardell F, et al. GATA6 activates Wnt signaling in pancreatic cancer by negatively regulating the Wnt antagonist Dickkopf-1. PLoS One 2011; 6:e22129; PMID:21811562; http://dx.doi.org/10.1371/journal.pone.0022129
33. Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K, Herlyn M. Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 2001; 20:8125-35; PMID:11781826; http://dx.doi.org/10.1038/sj.onc.1205034
34. Stender IM, Etoh T, Tsuchida T, Nakagawa H, Byers HR, Imokawa G, Ishibashi Y. Metastatic behavior and tumorigenicity of a human melanoma cell line (MM-RU) after injection into nude mice. J Dermatol 1993; 20:611-7; PMID:8277038
35. Vultur A, Villanueva J, Herlyn M. Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clin Cancer Res 2011; 17:1658-63; PMID:21447722; http://dx.doi.org/10.1158/1078-0432.CCR-10-0174
36. Munshi N, Jeay S, Li Y, Chen CR, France DS, Ashwell MA, Hill J, Moussa MM, Leggett DS, Li CJ. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010; 9:1544-53; PMID:20484018; http://dx.doi.org/10.1158/1535-7163.MCT-09-1173
37. Puri N, Salgia R. Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog 2008; 7:9; PMID:19240370; http://dx.doi.org/10.4103/1477-3163.44372
38. Yap TA, Olmos D, Brunetto AT, Tunariu N, Barriuso J, Riisnaes R, Pope L, Clark J, Futreal A, Germuska M, et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011; 29:1271-9; PMID:21383285; http://dx.doi.org/10.1200/JCO.2010. 31.0367
39. Shaw HM, Nathan PD. Vemurafenib in melanoma. Expert Rev Anticancer Ther 2013; 13:513-22; PMID:23617343; http://dx.doi.org/10.1586/era.13.24
40. Hu T, Li C. Convergence between Wnt-β-catenin and EGFR signaling in cancer. Mol Cancer 2010; 9:236; PMID:20828404; http://dx.doi.org/10.1186/1476- 4598-9-236
41. Efeyan A, Sabatini DM. mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol 2010; 22:169-76; PMID:19945836; http://dx.doi.org/10.1016/j.ceb. 2009.10.007
42. Jazirehi AR, Wenn PB, Damavand M. Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy. Am J Cancer Res 2012; 2:178-91; PMID:22485197
43. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12:9-22; PMID:17613433; http://dx.doi.org/10.1016/j.ccr.2007.05.008
44. Yamamoto H, Kishida S, Kishida M, Ikeda S, Takada S, Kikuchi A. Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3beta regulates its stability. J Biol Chem 1999; 274:10681-4; PMID:10196136; http://dx.doi.org/10.1074/jbc.274.16.10681
45. Sinnberg T, Menzel M, Ewerth D, Sauer B, Schwarz M, Schaller M, Garbe C, Schittek B. β-Catenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistance. PLoS One 2011; 6:e23429; PMID:21858114; http://dx.doi.org/10.1371/journal.pone.0023429
46. Mita MM, Mita A, Rowinsky EK. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther 2003; 2(Suppl 1):S169-77; PMID:14508096
47. Pópulo H, Lopes JM, Soares P. The mTOR Signalling Pathway in Human Cancer. Int J Mol Sci 2012; 13:1886-918; PMID:22408430; http://dx.doi.org/10. 3390/ijms13021886
48. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009; 461:614-20; PMID:19759537; http://dx.doi.org/10.1038/nature08356
49. O'Reilly T, McSheehy PM. Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals. Transl Oncol 2010; 3:65-79; PMID:20360931; http://dx.doi.org/10.1593/ tlo.09277
50. Busch AM, Johnson KC, Stan RV, Sanglikar A, Ahmed Y, Dmitrovsky E, Freemantle SJ. Evidence for tankyrases as antineoplastic targets in lung cancer. BMC Cancer 2013; 13:211; PMID:23621985; http://dx.doi.org/10.1186/1471-2407-13- 211
51. Puri N, Khramtsov A, Ahmed S, Nallasura V, Hetzel JT, Jagadeeswaran R, Karczmar G, Salgia R. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res 2007; 67:3529-34; PMID:17440059; http://dx.doi.org/10.1158/0008-5472.CAN- 06-4416
52. Laux I, Goldman J, Just R, Brady K, Li J, Schwartz B, Savage R, Garmey E, Rosen L. Phase I dose escalation trial (ARQ 197-111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinib. J Clin Oncol 2009; 27(15S):abstract 3549. Available from: http://meetinglibrary.asco.org/content/ 31504-65
53. Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, et al. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition. Mol Cancer Res 2010; 8:1142-51; PMID:20647329; http://dx.doi.org/10.1158/1541-7786. MCR-09-0388
54. Dillon R, Nilsson CL, Shi SD, Lee NV, Krastins B, Greig MJ. Discovery of a novel B-Raf fusion protein related to c-Met drug resistance. J Proteome Res 2011; 10:5084-94; PMID:21936566; http://dx.doi.org/10.1021/pr200498v
55. Schmid K, Bago-Horvath Z, Berger W, Haitel A, Cejka D, Werzowa J, Filipits M, Herberger B, Hayden H, Sieghart W. Dual inhibition of EGFR and mTOR pathways in small cell lung cancer. Br J Cancer 2010; 103:622-8; PMID:20683448; http://dx.doi.org/10.1038/sj.bjc.6605761
56. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149:274-93; PMID:22500797; http://dx.doi.org/10.1016/j.cell.2012.03. 017
57. Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol 2011; 23:744-55; PMID:21963299; http://dx.doi.org/10.1016/j.ceb.2011.09.003
58. Karbowniczek M, Spittle CS, Morrison T, Wu H, Henske EP. mTOR is activated in the majority of malignant melanomas. J Invest Dermatol 2008; 128:980-7; PMID:17914450; http://dx.doi.org/10.1038/sj.jid.5701074
59. Pópulo H, Soares P, Faustino A, Rocha AS, Silva P, Azevedo F, Lopes JM. mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics. Pigment Cell Melanoma Res 2011; 24:254-7; PMID:21029395; http://dx.doi.org/10.1111/j.1755-148X.2010.00796.x
60. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002; 4:648-57; PMID:12172553; http://dx.doi.org/10.1038/ncb839
61. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 2005; 280:32081-9; PMID:16027121; http://dx.doi.org/10.1074/jbc.M502876200
62. Choo AY, Roux PP, Blenis J. Mind the GAP: Wnt steps onto the mTORC1 train. Cell 2006; 126:834-6; PMID:16959561; http://dx.doi.org/10.1016/j.cell. 2006.08.025
63. Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H, Mills GB, Kobayashi R, Hunter T, Lu Z. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem 2007; 282:11221-9; PMID:17287208; http://dx.doi.org/10.1074/jbc.M611871200
64. Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M, Trent JM. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002; 1:279-88; PMID:12086864; http://dx.doi.org/10.1016/S1535-6108(02)00045-4
65. Pham K, Milovanovic T, Barr RJ, Truong T, Holcombe RF. Wnt ligand expression in malignant melanoma: pilot study indicating correlation with histopathological features. Mol Pathol 2003; 56:280-5; PMID:14514922; http://dx.doi.org/10.1136/mp.56.5.280
66. Da Forno PD, Pringle JH, Hutchinson P, Osborn J, Huang Q, Potter L, Hancox RA, Fletcher A, Saldanha GS. WNT5A expression increases during melanoma progression and correlates with outcome. Clin Cancer Res 2008; 14:5825-32; PMID:18794093; http://dx.doi.org/10.1158/1078-0432.CCR-07-5104
67. Flaherty KT. Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res 2006; 12:2366s-70s; PMID:16609060; http://dx.doi.org/10.1158/1078-0432.CCR-05-2505
68. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487:500-4; PMID:22763439; http://dx.doi.org/10.1038/nature11183
69. Fong JT, Jacobs RJ, Moravec DN, Uppada SB, Botting GM, Nlend M, Puri N. Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer. PLoS One 2013; 8:e78398; PMID:24223799; http://dx.doi.org/10.1371/journal.pone.0078398
70. Apte U, Zeng G, Muller P, Tan X, Micsenyi A, Cieply B, Dai C, Liu Y, Kaestner KH, Monga SP. Activation of Wnt/beta-catenin pathway during hepatocyte growth factor-induced hepatomegaly in mice. Hepatology 2006; 44:992-1002; PMID:17006939; http://dx.doi.org/10.1002/hep.21317
71. Liou GI, Matragoon S, Samuel S, Behzadian MA, Tsai NT, Gu X, Roon P, Hunt DM, Hunt RC, Caldwell RB, et al. MAP kinase and beta-catenin signaling in HGF induced RPE migration. Mol Vis 2002; 8:483-93; PMID:12500177
72. Huang FI, Chen YL, Chang CN, Yuan RH, Jeng YM. Hepatocyte growth factor activates Wnt pathway by transcriptional activation of LEF1 to facilitate tumor invasion. Carcinogenesis 2012; 33:1142-8; PMID:22436613; http://dx.doi.org/10. 1093/carcin/bgs131
73. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4:335-48; PMID:15122205; http://dx.doi.org/10.1038/nrc1362
74. Barker N. The canonical Wnt/beta-catenin signalling pathway. Methods Mol Biol 2008; 468:5-15; PMID:19099242; http://dx.doi.org/10.1007/978-1-59745-249-6- 1
75. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009; 17:9-26; PMID:19619488; http://dx.doi.org/10.1016/j.devcel.2009.06.016
76. Cadigan KM, Liu YI. Wnt signaling: complexity at the surface. J Cell Sci 2006; 119:395-402; PMID:16443747; http://dx.doi.org/10.1242/jcs.02826
77. Kawada I, Hasina R, Arif Q, Mueller J, Smithberger E, Husain AN, Vokes EE, Salgia R. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Res 2014; 74:884-95; PMID:24305878; http://dx.doi.org/10.1158/0008-5472.CAN-12-3583
78. Wu D, Pan W. GSK3: a multifaceted kinase in Wnt signaling. Trends Biochem Sci 2010; 35:161-8; PMID:19884009; http://dx.doi.org/10.1016/j.tibs.2009.10.002
79. Yun MS, Kim SE, Jeon SH, Lee JS, Choi KY. Both ERK and Wnt/beta-catenin pathways are involved in Wnt3a-induced proliferation. J Cell Sci 2005; 118:313-22; PMID:15615777; http://dx.doi.org/10.1242/jcs.01601
80. Byers HR, Etoh T, Doherty JR, Sober AJ, Mihm MC Jr. Cell migration and actin organization in cultured human primary, recurrent cutaneous and metastatic melanoma. Time-lapse and image analysis. Am J Pathol 1991; 139:423-35; PMID:1867326
81. Puri N, Eller MS, Byers HR, Dykstra S, Kubera J, Gilchrest BA. Telomere-based DNA damage responses: a new approach to melanoma. FASEB J 2004; 18:1373-81; PMID:15333580; http://dx.doi.org/10.1096/fj.04-1774com
82. Ramirez-Montagut T, Andrews DM, Ihara A, Pervaiz S, Pandolfi F, Van Den Elsen PJ, Waitkus R, Boyle LA, Hishii M, Kurnick JT. Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of melan-A/MART-1. Clin Exp Immunol 2000; 119:11-8; PMID:10606959; http://dx.doi.org/10.1046/j.1365-2249.2000.01089.x
83. Pandolfi F, Trentin L, Boyle LA, Stamenkovic I, Byers HR, Colvin RB, Kurnick JT. Expression of cell adhesion molecules in human melanoma cell lines and their role in cytotoxicity mediated by tumor-infiltrating lymphocytes. Cancer 1992; 69:1165-73; PMID:1739916; http://dx.doi.org/10.1002/cncr.2820690517
84. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005; 65:1479-88; PMID:15735036; http://dx.doi.org/10.1158/0008-5472.CAN-04-2650
85. Coley HM. Development of drug-resistant models. Methods Mol Med 2004; 88:267-73; PMID:14634238
86. Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E, Johnson BE, Salgia R. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002; 8:620-7; PMID:11839685
87. Puri N, Pitman RT, Mulnix RE, Erickson T, Iness AN, Vitali C, Zhao Y, Salgia R. Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides. Cancer Lett 2014; 343:14-23; PMID:24041868; http://dx.doi.org/10.1016/j.canlet. 2013.09.010
88. Turner DJ, Zirvi MA, Barany F, Elenitsas R, Seykora J. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction. J Cutan Pathol 2005; 32:334-9; PMID:15811117; http://dx.doi.org/10.1111/j.0303- 6987.2005.00338.x
89. Belaguli NS, Aftab M, Rigi M, Zhang M, Albo D, Berger DH. GATA6 promotes colon cancer cell invasion by regulating urokinase plasminogen activator gene expression. Neoplasia 2010; 12:856-65; PMID:21076612